Approach
The Company’s main focus has been on enhancing our sustainability framework, implementing the commitments we made by creating practical plans, and placing a greater emphasis on environmental aspects such as climate change, metrics, and reporting.
These efforts are led by General Counsel, Will Scrimshaw.
SUSTAINABILITY FRAMEWORK
Our path to delivering sustained social, financial and environmental value
At BenevolentAI we serve patients by leveraging our proprietary and validated Benevolent Platform™ that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well positioned to identify and accelerate novel drug discovery.
We are committed to weaving ESG stewardship into the fabric of our mission.
We concentrate our sustainability efforts around five core levers:
- Enhance our platform
- Advance our pipeline
- Support our partners
- Invest in our people
- Reduce our impact on the planet
We have identified the following sustainability issues as being the most material for our business and our stakeholders
Diversity and inclusion, attraction and development, safety and wellbeing, innovation, product quality, cybersecurity, ethical conduct, reducing waste and climate change.
- Deepen our pipeline
- Sustain our Leadership
- Extend our impact
- Build for the long term
We aim to complete a materiality assessment in 2024 to further our understanding of these issues.
Our Benevolent Platform™ integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases, with the goal of increasing the probability of clinical success.
Commitments
- Continue to enhance our Platform, ensuring we maintain our position as a leader in applying advanced AI to accelerate biopharma drug discovery and, in doing so, positively impact society and serve patients by improving R&D productivity.
Our goal is to contribute positively to society by pushing the boundaries of technology and science to address significant unmet medical needs by developing new medicines for a broad range of undertreated diseases.
Commitments
- Progress clinical and preclinical assets to meet development plan timelines.
- Progress early pipeline assets to internally agreed timelines.
- Maintain a steady-state Target ID discovery pipeline.
- Deliver the project plans of our collaborations with AstraZeneca and Merck.
Our goal is to maintain existing and establish new commercial and not-for-profit partnerships to put our Benevolent Platform™ to good use for wider societal benefit, and to deliver maximum impact to patients.
Commitments
- Increase our societal impact through long-term, mutually beneficial relationships.
- Deliver on the project plans with our current partners AstraZeneca and Merck.
- Uphold our ethical standards across our value chain.
Learn more
Partnerships and Collaborations DNDi
Our goal is to build an inclusive, supportive and engaging workplace that enables employees to collaborate, innovate and thrive. In doing so, we aim to attract, retain and develop exceptional and diverse talent to support our mission and drive future growth.
Commitments
- Attract, retain and develop our talent.
- Maintain our focus on culture and values.
- Promote diversity and inclusion.
- Inspire the next generation of future leaders from within.
Learn more
Culture Blog
We recognise the need to act swiftly and intentionally to mitigate our impact on climate change and are committed to reducing the environmental impact of our business activities by monitoring and reducing our emissions.
Commitments
- We endeavour to reduce our proportional impact on the environment as our business continues to evolve.
Emissions, energy and other environment data
1. Takes into consideration market-based scope 2 emissions.
GOVERNANCE
Governance for sustainability
As sustainability is cross-cutting across our business, the impact that we have is considered and guided at many levels. On a governance level, it is built into our Board structures and our robust corporate governance framework, which is bolstered by committees, groups and colleagues who feel empowered to instigate and drive activity within the business. This means many of our most impactful programmes are driven from the bottom up.
Commitment
We are committed to ensuring independence and diversity across our Board.
Commitment
Build a solid Board structure accompanied by all necessary committees to ensure robust governance.
Commitment
To maintain and further develop a suite of good corporate practices and policies where needed.
Commitment
We recognise the importance of protecting the intellectual property that is generated in the course of our work, while respecting the IP of others.
Commitment
Our commitment to effective risk management and business continuity is at the core of our operational excellence and strategic planning. We recognise that in today’s dynamic business environment, identifying and managing both existing and potential risks is crucial for sustaining growth, protecting assets, and ensuring the long-term success of our organisation. The Audit, Finance and Risk Committee of the Board has oversight of, and responsibility for, risk management across the Company. It is provided with regular updates covering key business risks at quarterly Board meetings.
Commitment
We commit to safeguarding the privacy rights of BenevolentAI’s employees and third parties, protecting our valuable data assets, and maintaining the security of our system infrastructures. We are dedicated to ensuring that our data protection and privacy compliance programme, as well as our information security strategies, are in line with our business objectives and comply with all applicable laws, regulations and leading data protection standards. We aim to manage and safeguard corporate information by implementing processes, roles, controls, and metrics that recognise information as an important business asset.